Liver Cancer

>

Latest News

Phase 3 EMERALD-1 trial results reveal that no new adverse events were identified with durvalumab plus bevacizumab in patients with unresectable HCC.
Durvalumab Plus Bevacizumab Improves PFS Outcomes in Unresectable HCC

January 17th 2025

Phase 3 EMERALD-1 trial results reveal that no new adverse events were identified with durvalumab plus bevacizumab in patients with unresectable HCC.

Data from a real-world study further illustrates clinical benefit in patients with cholangiocarcinoma receiving pemigatinib.
Real-world Data Supports Findings from FIGHT-202 in Cholangiocarcinoma

September 26th 2024

Updated findings from the CARES-310 trial support the resubmitted application for camrelizumab/rivoceranib in unresectable hepatocellular carcinoma.
Developers Resubmit NDA for Camrelizumab Combo in Unresectable Liver Cancer

September 24th 2024

Treatment with the tremelimumab-based combination also yielded no new serious treatment-related adverse effects in the HIMALAYA study.
Tremelimumab Combo Improves OS Vs Sorafenib in Unresectable Liver Cancer

September 17th 2024

Data from CCTG HE1 also show a numerical improvement an in overall survival with added radiotherapy over best supportive care alone.
Single-Fraction Radiotherapy Improves Pain in Hepatic Cancer

September 16th 2024

Latest CME Events & Activities

2025 GI Satellite Symposia in San Francisco

January 23-24, 2025

Register Now!

The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape

View More

Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®

View More

BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting

View More

PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?

View More

<1234